ORIC Pharmaceuticals Inc
ORICHealthcare|Biotechnology|USA
$10.85
-0.09 (-0.82%)
Tangible Book
$4.02
Earnings Power
$2.52
About
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Stock Price
-5.2%(1Y)
Pipeline Summary
9 total trials9
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 4Recruiting: 3Terminated: 2
Active Trials (3)
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421Metastatic Prostate Cancer
Phase 1Recruiting
Enrollment: 275 participants
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors
Phase 1Recruiting
Enrollment: 76 participants
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700Solid Tumors
Phase 1Phase 2Recruiting
Enrollment: 350 participants
BioScore
4/10
Cautious
Ownership
Recent Insider Trades
Heyman Richard A.SELL
2026-07-06300 shares @ $12
Piscitelli DominicSELL
2026-02-2452,000 shares @ $13.51
Heyman Richard A.SELL
2026-01-166,700 shares @ $12
Multani Pratik SSELL
2025-12-1610,720 shares @ $9.06
Piscitelli DominicSELL
2025-12-1610,720 shares @ $9.06
Data last updated: Jul 13, 2026, 12:47 PM